All In MedTech

Device Trial Radar · NCT07929467

Leadless Versus Conventional Pacemakers: Effects on Heart Function and Heart Failure

Leadless Pacing and Heart Failure: A Prospective, Randomized, Open-Label, Non-Inferiority Trial

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 760 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

760

Planned (sponsor's estimate)

Start

Nov 2027

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Karl Landsteiner University of Health SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 10, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

People with a slow heart rhythm may need a permanent pacemaker. Conventional pacemakers use a device placed under the skin and wires that pass through veins into the heart. Leadless pacemakers are placed directly inside the heart without a chest pocket or these wires. Both approaches can provide pacing, but their effects on heart function and heart-failure-related problems need to be compared. LEAP-HF will compare an indication-adapted leadless pacemaker strategy with a conventional transvenous pacemaker strategy in 760 adults for whom either approach is clinically appropriate. Participants must have a left ventricular ejection fraction above 40% and must not require a defibrillator, cardiac resynchronization therapy, or chronic atrial pacing. Participants will be assigned by chance, in equal proportions, to the two strategies. The device and pacing mode will be selected according to the participant's clinical indication within the assigned strategy. The main question is whether the leadless strategy is not unacceptably worse than the conventional strategy for pacing-induced cardiac dysfunction during 12 months of follow-up. This outcome includes a qualifying deterioration in heart pumping function, pacemaker syndrome, heart failure requiring hospitalization, or an upgrade to cardiac resynchronization therapy. The prespecified non-inferiority margin is an absolute difference of 7 percentage points. Assessments include heart ultrasound, pacemaker checks, an electrocardiogram, a blood test for NT-proBNP, symptom assessment, and questionnaires about health and quality of life. There will be a telephone contact at 6 weeks and in-person visits at 6 and 12 months after implantation. The study will also compare heart function, complications, further procedures, and deaths. Participants and treating teams will know which pacing system was implanted; selected clinical events will be reviewed by an independent committee unaware of the assigned treatment.

Conditions

  • Bradycardia
  • Atrioventricular Block
  • Heart Failure
  • Pacing Induced Cardiomyopathy
  • Pacing Therapy
  • Pacing Induced Dyssynchrony
  • Leadless Pacemaker

Interventions

  • Leadless pacemaker implantationDevice

    Implantation and indication-adapted programming of a leadless pacemaker system. The current protocol lists Medtronic Micra VR2, Medtronic Micra AV2, Abbott AVEIR VR, and Abbott AVEIR AR/VR dual-chamber systems. The selected system must be appropriate for the clinical indication and permitted by the applicable approvals and study protocol. Follow-up includes standardized device interrogation and assessment of ventricular pacing burden.

  • Conventional transvenous pacemaker implantationDevice

    Implantation and indication-adapted programming of a conventional transvenous single- or dual-chamber pacemaker with right ventricular pacing. The current protocol lists systems from Abbott, Biotronik, Boston Scientific, Medtronic, and MicroPort/Sorin. Device type and pacing mode are selected according to the prespecified clinical algorithm. Lead position, electrical parameters, programming, and right ventricular pacing burden are documented. Conduction system pacing is not part of the assigned strategy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative incidence of pacing-induced cardiac dysfunctionTime frame: Up to 12 months after implantation for clinical events; echocardiographic assessments at 6 and 12 months after implantation (each +/-30 days).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital St. Pölten, Department of Internal Medicine 3 - Cardiology

    Sankt Pölten, Lower Austria, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.